相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV
J. F. Bergmann et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Estimating the Net Contribution of Interleukin-28B Variation to Spontaneous Hepatitis C Virus Clearance
Julia di Iulio et al.
HEPATOLOGY (2011)
Treatment of chronic hepatitis B: Evolution over two decades
Man-Fung Yuen et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2011)
PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (G1/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12
S. Zeuzem et al.
JOURNAL OF HEPATOLOGY (2011)
TIMING AND FREQUENCY OF DEPRESSION DURING HCV-TREATMENT WITH CONTROLLED-RELEASE-IFNA2B (CR2B) VS. PEGYLATED-IFNA2B (PEG2B): RESULTS FROM SELECT-2, A RANDOMIZED-OPEN-LABEL-72-WEEK-COMPARISON IN 116 TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 HCV
W. A. Long et al.
JOURNAL OF HEPATOLOGY (2011)
Insights into the role of interferon lambda in hepatitis C virus infection
Heidi Barth
JOURNAL OF HEPATOLOGY (2011)
SVR FOR CONTROLLED-RELEASE INTERFERON ALPHA-2B (CR2B) +RIBAVIRIN COMPARED TO PEGYLATED INTERFERON ALPHA-2B (PEG2B) +RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 (G1) HEPATITIS C: FINAL RESULTS FROM SELECT-2
E. Lawitz et al.
JOURNAL OF HEPATOLOGY (2011)
Interferon-lambda serum levels in hepatitis C
Bettina Langhans et al.
JOURNAL OF HEPATOLOGY (2011)
Controlled release recombinant human interferon-α2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial
I. Dzyublyk et al.
JOURNAL OF VIRAL HEPATITIS (2011)
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Pegylated Interferons for the Treatment of Chronic Hepatitis C Pharmacological and Clinical Differences between Peginterferon-alpha-2a and Peginterferon-alpha-2b
Graham R. Foster
DRUGS (2010)
Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 1
Stefan Zeuzem et al.
GASTROENTEROLOGY (2010)
Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study
Andri Rauch et al.
GASTROENTEROLOGY (2010)
Peginterferon alpha-2a Is Associated with Higher Sustained Virological Response than Peginterferon alfa-2b in Chronic Hepatitis C: Systematic Review of Randomized Trials
Tahany Awad et al.
HEPATOLOGY (2010)
Polymorphism in Xeroderma Pigmentosum Complementation Group C Codon 939 and Aflatoxin B1-Related Hepatocellular Carcinoma in the Guangxi Population
Xi-Dai Long et al.
HEPATOLOGY (2010)
RANDOMIZED, OPEN-LABEL 12-WEEK COMPARISON OF CONTROLLED-RELEASE INTERFFRON ALPHA2B+RIBAVRIN VS. PEGYLATED-INTERFERON ALPHA2B+RIBAVRIN IN TREATMENT-NAIVE GENOTYPE1 HEPATITIS C: 4 WEEK RESULTS FROM 480STUDY (PANEL A)
Z. Krastev et al.
JOURNAL OF HEPATOLOGY (2010)
Pegylated interferons alpha 2a and alpha 2b in the treatment of chronic hepatitis C
Alessio Aghemo et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2010)
Safety and Antiviral Activity of Albinterferon Alfa-2b in Prior Interferon Nonresponders With Chronic Hepatitis C
David R. Nelson et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
RANDOMIZED TRIAL COMPARING SYSTEMIC AND LOCAL REACTIONS TO CONTROLLED-RELEASE INTERFERON ALPHA2B AND PEGYLATED-INTERFERON ALPHA2B IN HEPATITIS C PATIENTS WHO FAILED PRIOR TREATMENT
E. Lawitz et al.
JOURNAL OF HEPATOLOGY (2009)
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Dongliang Ge et al.
NATURE (2009)
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
David L. Thomas et al.
NATURE (2009)
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Vijayaprakash Suppiah et al.
NATURE GENETICS (2009)
Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
Yasuhito Tanaka et al.
NATURE GENETICS (2009)
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Novel controlled-release Lemna-derived IFN-α2b (Locteron):: Pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial
Leo G. J. De Leede et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2008)
IFN-lambda (IFN-λ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo
Caroline Sommereyns et al.
PLOS PATHOGENS (2008)
Pharmacokinetics, safety and biomarkers in man after administration of Locteron (TM), a once every two-weeks controlled release formulation of interferon-alpha
A. Bechet et al.
JOURNAL OF HEPATOLOGY (2006)
Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
GKK Lau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised
HLA Janssen et al.
LANCET (2005)
分享论文
